UNSPSC 51422209: Fluorometholone acetate

This classification denotes a therapeutic glucocorticoid C24H31FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I50C3I3OK, chemically known as pregna-1,4-diene-3,20-dione, 17-(acetyloxy)-9-fluoro-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)-, but more generally known as fluorometholone acetate, which bears US NIH Compound Identifier 240767. European Medicines Agency schedules Fluorometholone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13906MIG.

UNSPSC 51422209 Fluorometholone acetate is a Commodity code that nominally covers a specific ophthalmic corticosteroid product, but recent state and local procurement activity shows little direct relevance to the code's stated scope. The single recent opportunity tagged to this code — Seminole County, Florida's IFB60459723LAS for Naloxone and Drug Deactivation Systems posted June 30, 2026 — solicits emergency-response pharmaceuticals and harm-reduction equipment rather than fluorometholone acetate or any related ophthalmic therapeutic. The Texas Health and Human Services Commission's concurrent RFI HHS0017013 on Direct-to-Manufacturer Prescriptions, while addressing pharmaceutical procurement broadly, likewise does not target ophthalmic or corticosteroid products. This mismatch suggests the code may be miscategorized in recent state and local systems, or that the actual procurement activity under this code identifier does not reflect the product definition.

The geographic spread evident in posted opportunities centers on Florida and Texas, with Seminole County's naloxone procurement representing the only concrete solicitation activity. The county's IFB, with a response deadline of July 26, 2023 (note: this date predates the posting by nearly three years, indicating a likely data error in the source), requires quarterly deliveries of 1,900 naloxone units and 800 drug deactivation systems annually under a two-year term with one-year renewal option, with E-Verify compliance and standard commercial insurance. The Texas RFI, posted April 3, 2026 with the same response deadline, functions as preliminary market intelligence rather than a binding solicitation and does not specify award values or budget parameters. Given the absence of recent solicitations actually procuring fluorometholone acetate or closely related ophthalmic products at the state and local level, this code shows minimal current activity aligned to its nominal scope.